4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 27, 2026
CAR-T Immunotherapy Targeting CD19- ALL
(clinicaltrials.gov)
- P1/2 | N=100 | Not yet recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2029 ➔ Jun 2029
Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD22 • CD38 • CRLF2 • IL3RA • MME
April 24, 2026
CAR-T Immunotherapy Targeting CD19- ALL
(clinicaltrials.gov)
- P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2029 | Trial primary completion date: Jul 2021 ➔ Jul 2028
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD22 • CD38 • CRLF2 • IL3RA • MME
1 to 2
Of
2
Go to page
1